Recent data from PLOS Medicine paints a stark picture of regulatory misalignment in rare disease treatments. Among 814 FDA orphan drug approvals spanning 2011–2023, merely 29% secured corresponding EMA marketing authorisation while maintaining orphan designation. The statistics reveal an even more troubling pattern: one-third of FDA-approved orphan medications were refused approval by European regulators entirely. An additional 38% gained EMA approval but without orphan status recognition. The discordance has worsened over time, with drugs approved between 2017 and 2023 demonstrating substantially lower approval odds at EMA than those approved in earlier periods. Non-cancer orphan drugs fared particularly poorly in European evaluation. These figures underscore a critical regulatory fragmentation that directly impacts patient access to essential treatments for rare conditions.
Read the full article on GMJ Newsroom.
Was this article helpful?
